A Systematic Review of Patient Race, Ethnicity, Socioeconomic Status, and Educational Attainment in Prostate Cancer Treatment Randomised Trials—Is the Evidence Base Applicable to the General Patient Population?

[1]  E. V. Van Allen,et al.  Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. , 2022, JAMA oncology.

[2]  M. Cooperberg,et al.  Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. , 2022, European urology.

[3]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  K. D. Sørensen,et al.  Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction , 2021, Nature genetics.

[6]  H. Weir,et al.  Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017 , 2020, MMWR. Morbidity and mortality weekly report.

[7]  P. Kantoff,et al.  Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[8]  G. Kimura,et al.  A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study , 2019, International Journal of Clinical Oncology.

[9]  S. Coughlin.  A review of social determinants of prostate cancer risk, stage, and survival , 2019, Prostate international.

[10]  M. Terris,et al.  Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. , 2019, JAMA oncology.

[11]  H. Sung,et al.  A randomized, double‐blind, placebo‐controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation , 2019, The Prostate.

[12]  A. Smart,et al.  The under-representation of minority ethnic groups in UK medical research , 2017, Ethnicity & health.

[13]  Q. Wei,et al.  Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study , 2016, The Lancet.

[14]  Jae-Lyun Lee,et al.  Randomized phase II trial of docetaxel plus prednisolone with or without androgen deprivation treatment in castration-resistant prostate cancer. , 2016 .

[15]  J. Verne,et al.  Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010 , 2015, BMC Medicine.

[16]  Zulin Wang,et al.  Clinical Research of Tashinone IIA Combined with Endocrine Therapy in Treating Advanced-Stage Prostate Cancer , 2014, Cell Biochemistry and Biophysics.

[17]  Hiroyuki Takahashi,et al.  Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial , 2012, BMC Cancer.

[18]  T. Ichikawa,et al.  Additive effect of zoledronic acid on serum prostate‐specific antigen changes for hormone‐sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade , 2012, International journal of urology : official journal of the Japanese Urological Association.

[19]  Christopher U. Jones,et al.  Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.

[20]  H. Verkooijen,et al.  Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis , 2009, Cancer.

[21]  J. Witte,et al.  Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California , 2009, Cancer Causes & Control.

[22]  A. Jemal,et al.  Cancer mortality in the United States by education level and race. , 2007, Journal of the National Cancer Institute.

[23]  R. Katz,et al.  Willingness of minorities to participate in biomedical studies: confirmatory findings from a follow-up study using the Tuskegee Legacy Project Questionnaire. , 2007, Journal of the National Medical Association.

[24]  E. Emanuel,et al.  Are Racial and Ethnic Minorities Less Willing to Participate in Health Research? , 2005, PLoS medicine.

[25]  M. Cooperberg,et al.  Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). , 2020, European urology.

[26]  F. Saad,et al.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Kelty,et al.  National Institutes of Health Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research , 2007 .